Sue-Jean Lin Biography and Net Worth

Sue-Jean Lin has served as a member of our board of directors since June 2021. Ms Lin retired in April 2025 from Alcon (NYSE: ALC), a global leader in eye care, where she served as senior vice president and chief information officer. At Alcon, she played a key role in the company’s transformation into an independent, publicly traded organization. Prior to Alcon, Ms Lin was a member of the Hill-Rom executive leadership team, serving as senior vice president and chief information officer. There, she was instrumental in developing a new business model that enabled patient engagement and improved the effectiveness of biomedical professionals. Earlier in her career, she held multiple leadership roles at Allergan, including as the senior vice president and chief information officer, as well as the regional chief financial officer for commercial operations across Europe, Middle East, Africa, and Asia Pacific region. Ms Lin holds a bachelor’s degree in accounting and a master’s degree in business administration from the University of Nevada, Reno.

What is Sue-Jean Lin's net worth?: The estimated net worth of Sue-Jean Lin is at least $706.82 thousand as of November 24th, 2025. Lin owns 26,735 shares of Arcutis Biotherapeutics stock worth more than $706,820 as of January 22nd. This net worth evaluation does not reflect any other investments that Lin may own. Learn More about Sue-Jean Lin's net worth.
How do I contact Sue-Jean Lin?: The corporate mailing address for Lin and other Arcutis Biotherapeutics executives is 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE CA, 91361. Arcutis Biotherapeutics can also be reached via phone at 805-418-5006 and via email at [email protected]. Learn More on Sue-Jean Lin's contact information.
Has Sue-Jean Lin been buying or selling shares of Arcutis Biotherapeutics?: Sue-Jean Lin has not been actively trading shares of Arcutis Biotherapeutics during the past quarter. Most recently, Sue-Jean Lin sold 25,272 shares of the business's stock in a transaction on Monday, November 24th. The shares were sold at an average price of $30.78, for a transaction totalling $777,872.16. Following the completion of the sale, the director now directly owns 26,735 shares of the company's stock, valued at $822,903.30. Learn More on Sue-Jean Lin's trading history.
Who are Arcutis Biotherapeutics' active insiders?: Arcutis Biotherapeutics' insider roster includes Patrick Burnett (Insider), Scott Burrows (CFO), Bhaskar Chaudhuri (Director), Terrie Curran (Director), Larry Edwards (Insider), Halley Gilbert (Director), Patrick Heron (Director), Neha Krishnamohan (Director), Sue-Jean Lin (Director), Masaru Matsuda (General Counsel), David Topper (CFO), Patricia Turney (SVP), Latha Vairavan (CFO), Todd Watanabe (Insider), Todd Watanabe (CEO), and Howard Welgus (Director). Learn More on Arcutis Biotherapeutics' active insiders.
Are insiders buying or selling shares of Arcutis Biotherapeutics?: During the last year, Arcutis Biotherapeutics insiders bought shares 4 times. They purchased a total of 7,434 shares worth more than $99,276.66. During the last year, insiders at the sold shares 51 times. They sold a total of 551,438 shares worth more than $11,983,811.39. The most recent insider tranaction occured on January, 5th when insider Patrick Burnett sold 2,490 shares worth more than $72,160.20. Insiders at Arcutis Biotherapeutics own 9.4% of the company. Learn More about insider trades at Arcutis Biotherapeutics.
Information on this page was last updated on 1/5/2026.

Sue-Jean Lin Insider Trading History at Arcutis Biotherapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/24/2025	Sell	25,272	$30.78	$777,872.16	26,735

Sue-Jean Lin Buying and Selling Activity at Arcutis Biotherapeutics

Arcutis Biotherapeutics Company Overview

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Today's Range

Now: $26.65

$26.18

$27.08

50 Day Range

MA: $28.60

$22.86

$31.20

2 Week Range

Now: $26.65

$11.13

$31.77

Volume

1,699,224 shs

Average Volume

1,704,479 shs

Market Capitalization

$3.26 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.71